Clinical trials: Placebo Group
Diabetes Mellitus, Type 2
12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
The objective is to investigate the efficacy, safety and pharmacokinetics of three different doses of BI 10773 compared to placebo given for 12 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control.
- Trial name
- NCT00789035
- Testing
- BI 10773, metformin
- Where
- 74 sites in Argentina, Croatia and 11 more
- Volunteers
- 408 people
- Sponsor
- Boehringer Ingelheim
Pain, Multiple Sclerosis
A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin
To investigate the ability of a cannabis based medicine extract to relieve chronic refractory pain of neurological origin.
- Trial name
- NCT01606176
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Jazz Pharmaceuticals
Allergic Rhinoconjunctivitis
Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics
The purpose of this study is to evaluate the efficacy and safety of Lertal® as an add-on treatment for children affected by allergic rhinoconjunctivitis.
- Trial name
- NCT03365648
- Testing
- Lertal® + standard therapy
- Where
- 17 sites in Italy
- Volunteers
- 150 people
- Sponsor
- NTC srl
Crohn's Disease
Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.
- Trial name
- MAPUS (NCT01951326)
- Testing
- RHB-104
- Where
- 103 sites in United States, Australia and 8 more
- Volunteers
- 331 people
- Sponsor
- RedHill Biopharma Limited
Pain
Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee
The primary aim of this study is to investigate if AZD1386 is efficacious as an analgesic in patients with osteoarthritis of the knee and at what dose.
- Trial name
- OA19 (NCT00878501)
- Testing
- AZD1386
- Where
- 41 sites in Bulgaria, Canada and 5 more
- Volunteers
- 241 people
- Sponsor
- AstraZeneca
Chronic Troublesome Sialorrhea, Cerebral Palsy
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
The objective of this study is to investigate the efficacy and safety of NT 201 compared with placebo for the treatment of chronic troublesome sialorrhea associated with neurological disorders (e.g.
- Conditions
- Chronic Troublesome Sialorrhea, Cerebral Palsy, Stroke, Traumatic Brain Injury
- Trial name
- SIPEXI (NCT02270736)
- Testing
- NT 201
- Where
- 31 sites in Georgia, Hungary and 4 more
- Volunteers
- 256 people
- Sponsor
- Merz Pharmaceuticals GmbH
Obsessive-Compulsive Disorder
Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder
The purpose of this study is to determine if a drug called topiramate is safe and effective as an add-on therapy in the treatment of Obsessive-Compulsive Disorder (OCD).
- Trial name
- NCT00187928
- Testing
- Topiramate
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- University of Florida
URTICARIA
Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria
The objective of this study is to evaluate the efficacy and safety of rupatadine for the treatment of CIU symptoms.To assess the clinical efficacy of a dose ranging of rupatadine fumarate (5mg, 10mg, and 20 mg) compared with…
- Trial name
- NCT00199238
- Testing
- Rupatadine Fumarate
- Where
- France
- Volunteers
- 248 people
- Sponsor
- J. Uriach and Company
Bronchial Asthma
BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients
The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product in adult patients with asthma.
- Trial name
- NCT03394989
- Testing
- Fluticasone propionate/salmeterol 100/50 µg, Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
- Where
- United States
- Volunteers
- 1,366 people
- Sponsor
- Cipla Ltd.
Healthy
To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days
To investigate the safety and tolerability of TC-5214 following oral administration of single and multiple ascending doses compared to placebo.
- Trial name
- NCT01145768
- Testing
- TC-5214
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
This trial will compare the use of fixed dose combination of empagliflozin and linagliptin to linagliptin alone in patient with type 2 diabetes mellitus
- Trial name
- NCT02453555
- Testing
- Linagliptin, Empagliflozin + linagliptin low dose, Empagliflozin + linagliptin high dose
- Where
- 40 sites in Japan
- Volunteers
- 275 people
- Sponsor
- Boehringer Ingelheim
Primary Biliary Cholangitis
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.
- Trial name
- NCT06247735
- Testing
- K-808 (Dose A), K-808 (Dose B)
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 46 people
- Sponsor
- Kowa Research Institute, Inc.
Acute Bronchitis
To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis
A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients with Acute Bronchitis
- Trial name
- NCT07061925
- Testing
- ALC-2203-1, ALC-2203-2, ALC-2203-AC
- Where
- South Korea
- Volunteers
- 169 people
- Sponsor
- Korea Arlico Pharm. Co., Ltd
Heart Diseases, Hypertension, Pulmonary
Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery
Endothelin-1 is a powerful substance that may be involved in causing hemodynamic instability (problems related to unstable blood pressure) during and after open heart surgery.
- Trial name
- NCT00458276
- Testing
- tezosentan
- Where
- 33 sites in United States, Austria and 12 more
- Volunteers
- 274 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Primary Objective: To demonstrate the superiority of Sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control with metformin.
- Trial name
- NCT02926950
- Testing
- Sotagliflozin (SAR439954), Metformin
- Where
- 93 sites in United States, Canada and 2 more
- Volunteers
- 518 people
- Sponsor
- Lexicon Pharmaceuticals
Autoimmune Haemolytic Anaemia
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female…
- Trial name
- LUMINA 3 (NCT07086976)
- Testing
- rilzabrutinib
- Where
- 105 sites in United States, Argentina and 16 more
- Volunteers
- 90 people
- Sponsor
- Sanofi
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-3 (NCT00348140)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg
- Where
- 194 sites in United States, Australia and 20 more
- Volunteers
- 1,468 people
- Sponsor
- GlaxoSmithKline
Uterine Fibroids
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
The primary objective of this study was to show superiority of vilaprisan in the treatment of heavy menstrual bleeding (HMB) in subjects with uterine fibroids compared to placebo The secondary objectives of this study were to…
- Trial name
- NCT03400956
- Testing
- Vilaprisan (BAY1002670)
- Where
- 87 sites in United States, Czechia and 3 more
- Volunteers
- 103 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
The primary objective of this study is to determine if there will be a greater mean reduction from baseline in glycated hemoglobin (HbA1c) achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin or…
- Trial name
- NCT03199053
- Testing
- Dapagliflozin, Saxagliptin
- Where
- 122 sites in United States, Argentina and 21 more
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
Asthma
Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma
In both parts, the primary comparisons of interest are between the percentage of patients with drug-related adverse events at each dose and placebo during single and multiple dosing regimens.
- Trial name
- NCT03971539
- Testing
- BI 894416
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.